Pathology & Oncology Research

, 15:445 | Cite as

Platinum-Based Chemotherapy in Lung Cancer Affects the Expression of Certain Biomarkers Including ERCC1

  • Judit Pápay
  • Zoltán Sápi
  • Gábor Egri
  • Márton Gyulai
  • Béla Szende
  • György Losonczy
  • József Tímár
  • Judit Moldvay
Original Paper

Abstract

Chemotherapies are widely used in the treatment of lung cancer. However, little is known about their effect in the expression of different tissue markers. Seventeen lung cancer tissue blocks obtained by bronchoscopic biopsies together with their corresponding surgical biopsies after neoadjuvant chemotherapy were studied. They included 9 adenocarcinomas (ADC) and 8 squamous cell carcinomas (SCC). Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues to study the expression of Ki-67, p53, Bcl-2, Bax, Fas-ligand and ERCC1 (excision repair cross-complementation group 1). Out of 17 NSCLC 6 expressed proapoptotic markers and 4 expressed antiapoptotic markers, while in 7 cases the apoptotic markers did not show detectable changes after neoadjuvant chemotherapy. Six of 17 bronchoscopic NSCLC cases expressed increased level of Ki-67 after neoadjuvant treatment. Eight bronchoscopic NSCLC tissues (6 SCC, 2 ADC) expressed ERCC1. All but one ADC became ERCC1 negative after neoadjuvant therapy. There was no newly expressed ERCC1 positive case in the surgical biopsy group. Platinum-based neoadjuvant chemotherapy had no effect on the apoptotic activity of 17 patients’ tumor specimen, however, 6 of 17 bronchoscopic NSCLC cases expressed increased level of Ki-67 after neoadjuvant treatment, in 3 cases the level of Ki-67 became decreased, while 8 cases had no detectable change of proliferation activity. The results of the present study suggest that platinum-based chemotherapy probably induces a selection of tumor cells with more aggressive phenotype, and also affects the expression of tissue marker (ERCC1) that could have predictive value.

Keywords

Chemotherapy Immunohistochemistry Lung cancer Molecular biology Neoadjuvant treatment 

Abbreviations

NSCLC

non-small cell lung cancer

ADC

adenocarcinoma

SCC

squamous cell carcinoma

BAC

bronchiolo-alveolar carcinoma

ERCC1

excision repair cross-complementation group 1

References

  1. 1.
    U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2002–2004 Incidence and Mortality Web-based Report Version. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2007Google Scholar
  2. 2.
    Noble J, Ellis PM, Mackay JA et al (2006) Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 9:1042–58CrossRefGoogle Scholar
  3. 3.
    Junker K, Langner K, Klinke F et al (2001) Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest. 120(5):1584–91CrossRefPubMedGoogle Scholar
  4. 4.
    Morero JL, Poleri C, Martin C et al (2007) Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA/IIIB NSCLC patients. J Thorac Oncol. 4:293–8Google Scholar
  5. 5.
    Ikuta K, Takemura K, Kihara M et al (2005) Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells. Oncol Rep. 13(6):1229–34PubMedGoogle Scholar
  6. 6.
    Filipits M, Pirker R, Dunant A et al (2007) Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol. 25(19):2735–40CrossRefPubMedGoogle Scholar
  7. 7.
    Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–91CrossRefPubMedGoogle Scholar
  8. 8.
    Rigas JR, Kelly K (2007) Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol. 2(Suppl 2):S77–85CrossRefPubMedGoogle Scholar
  9. 9.
    Gilligan D, Nicolson M, Smith I et al (2007) Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 369(9577):1929–37CrossRefPubMedGoogle Scholar
  10. 10.
    de Marinis F, Tedesco B, Treggiari S et al (2007) Role of induction chemotherapy in resectable N2 non-small cell lung cancer. J Thorac Oncol. 5(Suppl 5):S31–4CrossRefGoogle Scholar
  11. 11.
    Abratt RP, Lee JS, Han JY et al (2006) Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer. J Thorac Oncol. 2:135–40CrossRefGoogle Scholar
  12. 12.
    Stinchcombe TE, Socinski MA (2007) The role of induction therapy for resectable non-small cell lung cancer. Drugs. 67(3):321–32CrossRefPubMedGoogle Scholar
  13. 13.
    De Pauw R, van Meerbeeck JP (2007) Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer. Curr Opin Oncol. 19(2):92–7CrossRefPubMedGoogle Scholar
  14. 14.
    Meert AP, Martin B, Verdebout JM et al (2004) Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer. 44(3):295–301CrossRefPubMedGoogle Scholar
  15. 15.
    Lang DS, Droemann D, Schultz H et al (2007) A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy. Respir Res. 14;8:43Google Scholar
  16. 16.
    Fujii T, Toyooka S, Ichimura K et al (2008) ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59(3):377–84CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2009

Authors and Affiliations

  • Judit Pápay
    • 1
  • Zoltán Sápi
    • 1
  • Gábor Egri
    • 2
  • Márton Gyulai
    • 3
  • Béla Szende
    • 1
  • György Losonczy
    • 4
  • József Tímár
    • 5
  • Judit Moldvay
    • 4
  1. 1.I. Institute of Pathology and Experimental Cancer ResearchSemmelweis UniversityBudapestHungary
  2. 2.Department of SurgeryBajcsy HospitalBudapestHungary
  3. 3.County Hospital of PulmonologyTorokbalintHungary
  4. 4.Department of PulmonologySemmelweis University BudapestBudapestHungary
  5. 5.II. Institute of PathologySemmelweis University BudapestBudapestHungary

Personalised recommendations